Alkem Laboratories Financial Statements
Alkem Laboratories Quarterly Results
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | 6.24 | 29.90 | 12.90 | 15.50 |
| Op profit growth | 31.80 | 43.30 | 2.95 | 17.10 |
| EBIT growth | 43.50 | 35 | (2.80) | 1.01 |
| Net profit growth | 40.60 | 78.60 | (29) | 20.30 |
| Profitability ratios (%) | ||||
| OPM | 21.90 | 17.70 | 16 | 17.60 |
| EBIT margin | 21.40 | 15.90 | 15.30 | 17.80 |
| Net profit margin | 17.90 | 13.50 | 9.82 | 15.70 |
| RoCE | 21.70 | 18.40 | 16.70 | 20.10 |
| RoNW | 5.85 | 5.11 | 3.38 | 5.47 |
| RoA | 4.52 | 3.92 | 2.69 | 4.44 |
| Per share ratios () | ||||
| EPS | 135 | 96.10 | 53.40 | 74.50 |
| Dividend per share | 30 | 25 | 13 | 15 |
| Cash EPS | 110 | 73.10 | 40.80 | 66.10 |
| Book value per share | 617 | 515 | 407 | 374 |
| Valuation ratios | ||||
| P/E | 20.50 | 24.20 | 37 | 29.60 |
| P/CEPS | 25.30 | 31.80 | 48.40 | 33.40 |
| P/B | 4.49 | 4.52 | 4.86 | 5.91 |
| EV/EBIDTA | 15.10 | 18 | 21.40 | 24 |
| Payout (%) | ||||
| Dividend payout | -- | -- | 24.60 | 9.68 |
| Tax payout | (12) | (8.80) | (31) | (6.20) |
| Liquidity ratios | ||||
| Debtor days | 67 | 59.70 | 51 | 41.10 |
| Inventory days | 85 | 71.30 | 75.30 | 67.90 |
| Creditor days | (53) | (51) | (58) | (51) |
| Leverage ratios | ||||
| Interest coverage | (32) | (20) | (18) | (22) |
| Net debt / equity | -- | 0.08 | 0.09 | 0.06 |
| Net debt / op. profit | (0.10) | 0.36 | 0.41 | 0.26 |
| Cost breakup () | ||||
| Material costs | (39) | (40) | (39) | (39) |
| Employee costs | (18) | (18) | (19) | (18) |
| Other costs | (20) | (24) | (26) | (26) |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Revenue | 8,865 | 8,344 | 6,422 | 5,688 |
| yoy growth (%) | 6.24 | 29.90 | 12.90 | 15.50 |
| Raw materials | (3,498) | (3,345) | (2,513) | (2,222) |
| As % of sales | 39.50 | 40.10 | 39.10 | 39.10 |
| Employee costs | (1,621) | (1,505) | (1,192) | (1,004) |
| As % of sales | 18.30 | 18 | 18.60 | 17.70 |
| Other costs | (1,803) | (2,021) | (1,689) | (1,463) |
| As % of sales | 20.30 | 24.20 | 26.30 | 25.70 |
| Operating profit | 1,942 | 1,473 | 1,028 | 999 |
| OPM | 21.90 | 17.70 | 16 | 17.60 |
| Depreciation | (275) | (253) | (143) | (101) |
| Interest expense | (59) | (65) | (55) | (45) |
| Other income | 233 | 104 | 96 | 112 |
| Profit before tax | 1,842 | 1,260 | 926 | 965 |
| Taxes | (224) | (110) | (288) | (60) |
| Tax rate | (12) | (8.80) | (31) | (6.20) |
| Minorities and other | (33) | (22) | (7.50) | (13) |
| Adj. profit | 1,585 | 1,127 | 631 | 892 |
| Exceptional items | -- | -- | -- | -- |
| Net profit | 1,585 | 1,127 | 631 | 892 |
| yoy growth (%) | 40.60 | 78.60 | (29) | 20.30 |
| NPM | 17.90 | 13.50 | 9.82 | 15.70 |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Profit before tax | 1,842 | 1,260 | 926 | 965 |
| Depreciation | (275) | (253) | (143) | (101) |
| Tax paid | (224) | (110) | (288) | (60) |
| Working capital | 3,976 | 2,089 | 660 | -- |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | 5,319 | 2,986 | 1,155 | 804 |
| Capital expenditure | 2,599 | 1,862 | 1,065 | -- |
| Free cash flow | 7,918 | 4,848 | 2,220 | 804 |
| Equity raised | 8,347 | 7,985 | 8,032 | 8,067 |
| Investments | (255) | (219) | (64) | -- |
| Debt financing/disposal | 1,012 | 1,037 | 902 | 545 |
| Dividends paid | -- | -- | 155 | 71.70 |
| Other items | -- | -- | -- | -- |
| Net in cash | 17,022 | 13,650 | 11,246 | 9,487 |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
| Equity capital | 23.90 | 23.90 | 23.90 | 23.90 |
| Preference capital | -- | -- | -- | -- |
| Reserves | 7,353 | 6,137 | 5,415 | 4,840 |
| Net worth | 7,377 | 6,161 | 5,439 | 4,864 |
| Minority interest | ||||
| Debt | 1,707 | 1,616 | 944 | 998 |
| Deferred tax liabilities (net) | 174 | 167 | 359 | 311 |
| Total liabilities | 9,439 | 8,092 | 6,875 | 6,294 |
| Fixed assets | 3,186 | 3,271 | 3,023 | 2,665 |
| Intangible assets | ||||
| Investments | 333 | 261 | 324 | 444 |
| Deferred tax asset (net) | 1,282 | 1,100 | 1,066 | 965 |
| Net working capital | 2,648 | 2,367 | 1,800 | 1,643 |
| Inventories | 2,312 | 1,819 | 1,500 | 1,442 |
| Inventory Days | 95.20 | 79.60 | -- | 82 |
| Sundry debtors | 1,607 | 1,649 | 1,248 | 1,081 |
| Debtor days | 66.20 | 72.10 | -- | 61.40 |
| Other current assets | 982 | 920 | 744 | 802 |
| Sundry creditors | (1,069) | (954) | (962) | (961) |
| Creditor days | 44 | 41.70 | -- | 54.60 |
| Other current liabilities | (1,185) | (1,067) | (730) | (720) |
| Cash | 1,990 | 1,092 | 662 | 577 |
| Total assets | 9,439 | 8,092 | 6,875 | 6,294 |
- Switch to
-
ConsolidatedStandalone
| Particulars ( Rupees In Crores.) | Jun-2021 | Mar-2021 | Dec-2020 | Sep-2020 | Jun-2020 |
|---|---|---|---|---|---|
| Gross Sales | 2,731 | 2,192 | 2,318 | 2,363 | 1,992 |
| Excise Duty | -- | -- | -- | -- | -- |
| Net Sales | 2,731 | 2,192 | 2,318 | 2,363 | 1,992 |
| Other Operating Income | -- | -- | -- | -- | -- |
| Other Income | 46.70 | 46.30 | 96.40 | 35.50 | 55 |
| Total Income | 2,778 | 2,238 | 2,414 | 2,398 | 2,047 |
| Total Expenditure ** | 2,139 | 1,901 | 1,789 | 1,762 | 1,470 |
| PBIDT | 640 | 337 | 626 | 636 | 577 |
| Interest | 12.90 | 10.70 | 13.10 | 18 | 17.10 |
| PBDT | 627 | 327 | 612 | 618 | 560 |
| Depreciation | 70.50 | 68.50 | 69 | 70.20 | 66.80 |
| Minority Interest Before NP | -- | -- | -- | -- | -- |
| Tax | 118 | 81.10 | 101 | 114 | 100 |
| Deferred Tax | (42) | (72) | (22) | (48) | (31) |
| Reported Profit After Tax | 480 | 249 | 464 | 482 | 423 |
| Minority Interest After NP | 12.10 | 9.23 | 12.90 | 9.45 | 1.18 |
| Net Profit after Minority Interest | 468 | 240 | 451 | 472 | 422 |
| Extra-ordinary Items | -- | -- | -- | -- | -- |
| Adjusted Profit After Extra-ordinary item | 468 | 240 | 451 | 472 | 422 |
| EPS (Unit Curr.) | 39.20 | 20.10 | 37.70 | 39.50 | 35.30 |
| Book Value (Unit Curr.) | -- | -- | -- | -- | -- |
| Dividend (%) | -- | -- | 1,250 | -- | -- |
| Equity | 23.90 | 23.90 | 23.90 | 23.90 | 23.90 |
| Public Shareholding (Number) | -- | -- | -- | -- | -- |
| Public Shareholding (%) | -- | -- | -- | -- | -- |
| Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| Non Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| PBIDTM(%) | 23.40 | 15.40 | 27 | 26.90 | 28.90 |
| PBDTM(%) | 22.90 | 14.90 | 26.40 | 26.20 | 28.10 |
| PATM(%) | 17.60 | 11.40 | 20 | 20.40 | 21.20 |
QuickLinks for Alkem Laboratories Ltd.
